Education
About Us
Working with TipRanks
Follow Us
Seer (SEER)
NASDAQ:SEER
Earnings Data
Report Date
May 12, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.28Last Year’s EPS
-0.34Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong commercial and scientific momentum (notably 67% installed base growth, ~69% consumable growth, doubling of publications, product launches, and a solid cash runway of ~$241M) alongside persistent headwinds from customer funding uncertainty, elongated sales cycles, modest 2026 guidance (~3% midpoint growth) and continued sizable net losses. Management emphasized innovation and long-term upside from large population studies and product roadmap milestones, while taking a conservative near-term view given NIH-related and macro funding risks.Company Guidance
Full Year Revenue Growth
Total revenue for 2025 was $16.6 million, representing 17% year-over-year growth versus $14.2 million in 2024; when excluding related party revenue, total revenue growth was approximately 33% year-over-year.
Quarterly Revenue and Product Mix
Q4 2025 revenue was $4.2 million, up 5% year-over-year from $4.0 million in Q4 2024; Q4 product revenue was $2.8 million and service revenue was $1.2 million. Excluding related party revenue, Q4 revenue grew ~16% YoY.
Strong Installed Base Expansion
Installed base increased to 82 instruments at year-end 2025, a 67% increase from 49 instruments at year-end 2024; approximately 60% of 2025 installs were under the Strategic Instrument Placement Program (SIPP).
Meaningful Consumable Volume Growth
Consumable kit volume increased approximately 69% year-over-year in 2025, demonstrating higher utilization of the Proteograph platform; calculated consumable pull-through per instrument was approximately $113,000 (noting methodological caveats).
Expanding Scientific Validation and Publications
Cumulative peer-reviewed publications nearly doubled from 36 at the end of 2024 to 70 at the end of 2025 (≈94% increase), including high-profile papers in Nature and Nature Genetics and multiple presentations/posters at HUPO 2025.
Commercial Milestone via Customer Launch
Customer PrognomIQ commercially launched ProVue Lung, a proteomics-based LDT for early lung cancer detection in November 2025; Seer holds approximately a 20% fully diluted interest in PrognomIQ.
Product and R&D Progress
Launched Proteograph ONE (3rd-generation assay) and SP200 (2nd-generation automation instrument) in June 2025 enabling throughput >1,000 samples/week (nearly 10x vs 112 samples/week in 2021); roadmap includes PAS v4 with AI/LLM interface in 2026 and a proteoform profiling assay planned for 2027.
Improved Financial Discipline and Cash Position
Operating expenses and stock-based compensation declined (total operating expenses down 19% YoY to $86.5M in 2025); net loss improved to $73.6M in 2025 from $86.6M in 2024. Free cash flow loss improved to ~$45.6M (2025) from $49.4M (2024). Cash, cash equivalents and investments were approximately $241M at year-end 2025.
Share Repurchases and Capital Allocation
Repurchased ~5.3 million Class A shares in 2025 for ≈$10.2M; total repurchases ~11.7M shares (≈$22M) since program inception, reducing shares outstanding by ~13%; Board authorized an additional $25M repurchase program.
Large-Scale Study Selections
Proteograph was selected for multiple population-scale studies in 2025, including a 20,000-sample study with Korea University and a 10,000-sample project with Discovery Life Sciences, demonstrating scalability for large cohorts.
SEER Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SEER Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $2.08 | $1.72 | -17.31% |
Nov 06, 2025 | $2.16 | $2.09 | -3.24% |
Aug 06, 2025 | $2.06 | $2.01 | -2.43% |
May 13, 2025 | $1.92 | $2.11 | +9.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Seer (SEER) report earnings?
Seer (SEER) is schdueled to report earning on May 12, 2026, After Close (Confirmed).
What is Seer (SEER) earnings time?
Seer (SEER) earnings time is at May 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SEER EPS forecast?
SEER EPS forecast for the fiscal quarter 2026 (Q1) is -0.28.